In 2006, Cardinale et al. demonstrated that ACE inhibitors and β-blockers were beneficial in adults with anthracycline-related cardiomyopathy if therapy is initiated soon after diagnosing LV dysfunction [63]. The gene discussed is ACE; the disease is cardiomyopathy.